Page 128 - Read Online

Page 783 Wong et al. Cancer Drug Resist 2023;6:768-87 https://dx.doi.org/10.20517/cdr.2023.58

27. Zhuang W, Ma J, Chen X, et al. The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene
panel. J Cancer 2018;9:2302-7. DOI PubMed PMC
28. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating
immunosurveillance. Immunity 2013;39:74-88. DOI PubMed
29. Garg AD, More S, Rufo N, et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology
2017;6:e1386829. DOI PubMed PMC
30. Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast
cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol 2019;5:334-42. DOI PubMed PMC
31. Tolaney SM, Kalinsky K, Kaklamani VG, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer
(ENHANCE 1): a phase Ib/II study. Clin Cancer Res 2021;27:3061-8. DOI
32. FDA. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer.
Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-
locally-advanced-or-metastatic-triple-negative. [Last accessed on 15 Nov 2023].
33. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med
2018;379:2108-21. DOI
34. Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III
trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Ann Oncol 2021;32:994-1004. DOI PubMed
35. Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic
triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 2021;32:983-93. DOI PubMed
36. Weis LN, Tolaney SM, Barrios CH, Barroso-Sousa R. Tissue-agnostic drug approvals: how does this apply to patients with breast
cancer? NPJ Breast Cancer 2021;7:120. DOI PubMed PMC
37. Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-
deficient (dMMR) solid cancers: results from GARNET study. JCO 2021;39:9. DOI
38. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the
setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100. DOI PubMed
39. Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women
with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020;6:676-84.
DOI PubMed
40. FDA. Updated time and public participation information: February 9, 2021: meeting of the oncologic drugs advisory committee
meeting announcement. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-and-
public-participation-information-february-9-2021-meeting-oncologic-drugs-advisory. [Last accessed on 15 Nov 2023].
41. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med
2022;386:556-67. DOI
42. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and
anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer
(IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020;396:1090-100. DOI
43. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in
triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol
2022;33:534-43. DOI PubMed
44. Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-
based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann
Oncol 2019;30:1279-88. DOI
45. Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized
GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in
early triple-negative breast cancer (TNBC). JCO 2021;39:506. DOI
46. Conte PF, Dieci MV, Bisagni G, et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab
for high-risk triple negative breast cancer patients: the A-BRAVE trial. JCO 2020;38:TPS598. DOI
47. Saji S, Mcarthur HL, Ignatiadis M, et al. ALEXANDRA/IMpassion030: a phase 3 study of standard adjuvant chemotherapy with or
without atezolizumab in patients with early-stage triple-negative breast cancer. JCO 2021;39:TPS597. DOI
48. Cortés J, André F, Gonçalves A, et al. IMpassion132 phase III trial: atezolizumab and chemotherapy in early relapsing metastatic
triple-negative breast cancer. Future Oncol 2019;15:1951-61. DOI
49. de Melo Gagliato D, Buzaid AC, Perez-Garcia J, Cortes J. Immunotherapy in breast cancer: current practice and clinical challenges.
BioDrugs 2020;34:611-23. DOI PubMed
50. El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: a report from the international immuno-oncology
biomarker working group. NPJ Breast Cancer 2021;7:150. DOI PubMed PMC
51. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast
cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40-50. DOI
52. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant